The emergence of the nicotinamide riboside kinases in the regulation of NAD\(^+\) metabolism

Rachel S Fletcher and Gareth G Lavery

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

Correspondence should be addressed to G G Lavery: g.g.lavery@bham.ac.uk

Abstract

The concept of replenishing or elevating NAD\(^+\) availability to combat metabolic disease and ageing is an area of intense research. This has led to a need to define the endogenous regulatory pathways and mechanisms cells and tissues utilise to maximise NAD\(^+\) availability such that strategies to intervene in the clinical setting are able to be fully realised. This review discusses the importance of different salvage pathways involved in metabolising the vitamin B3 class of NAD\(^+\) precursor molecules, with a particular focus on the recently identified nicotinamide riboside kinase pathway at both a tissue-specific and systemic level.

NAD\(^+\) as a redox cofactor and signalling molecule

The vital role of NAD\(^+\) in redox metabolism was first described in 1906 by Arthur Harden as being a required cofactor for alcohol fermentation (Harden & Young 1906). It has since been well established as a redox coenzyme necessary for many redox reactions (Euler-Chelpin 1966). During these redox events NAD\(^+\) can be reduced by accepting electrons from donor molecules or, in reverse, NADH can be oxidised to NAD\(^+\) by donating electrons. This interchange of electrons allows catalysis of reversible transhydrogenase reactions (Warburg & Christian 1936). Notably, NAD\(^+\) redox reactions are vital in energy production pathways such as glycolysis, oxidative phosphorylation and fatty acid oxidation. Typically NAD\(^+\) is predominantly found in its oxidised form with NAD/NADH ratios varying from 10/1 to 700/1 and a total cellular concentration thought to be estimated between 0.3–1.0\,\text{mM} in mammalian cells (Veech et al. 1972, Casazza & Veech 1986). Alternatively, NAD\(^+\) can be phosphorylated to NADP\(^+\) by NAD kinase and likewise this also exists in its reduced form NADPH. NADP(H) concentrations are estimated at 10\% of total NAD(H) levels (Veech et al. 1972, Casazza & Veech 1986). NADPH acts as an essential reducing agent aiding many anabolic pathways including nucleic acid and lipid biosynthesis (Berget et al. 2004, Tedeschi et al. 2016).

More recently, NAD\(^+\) has been recognised as an important signalling molecule that is consumed upon the activity of several enzymes including sirtuins (SIRTs), poly-ADP-ribose polymerases (PARPs) and cyclic ADP-ribose synthases (cADPR\(\text{ss}\)) (Houtkooper et al. 2010, Dolle et al. 2013). This new found purpose highlighted that NAD\(^+\), previously thought of as a stable molecule, is actually in continuous turnover and tightly regulated to maintain metabolic homeostasis. In fact, with approximately 2.5 ATP molecules formed per pair of electrons donated by NADH in the electron transport chain, and an estimated 80\,\text{kg} of ATP turned over by an adult male each day, it is predicted as much as 30\,\text{kg} NADH is generated every day, reinforcing the need for regulated maintenance of NAD(H) biosynthetic pathways (Kornberg 1991, Walsh et al. 2018).
SIRTs are important for metabolic energy control, whereby induction of SIRTs results in posttranslational modifications, such as deacetylation of substrate lysine residues, typically in an NAD⁺-dependent manner (Dali-Youcef et al. 2007, Houtkooper et al. 2012). Following activation, generally at times of energy deficit and concomitant with a rise in NAD⁺ content, SIRT activity (most notably SIRT1 and SIRT3) leads to metabolic adaptation in favour of more efficient ATP generation for example by enhancing mitochondrial content and capacity (Rodgers et al. 2005, Rodgers & Puigserver 2007, Feige et al. 2008, Canto et al. 2009, 2010, Hirschey et al. 2010, Jing et al. 2011, 2013). In models of SIRT1 and SIRT3 deficiency, metabolic impairments were detected particularly following metabolic challenge (Boily et al. 2008, Hirschey et al. 2010, Xu et al. 2010, Kendrick et al. 2011, Purushotham et al. 2012, Jing et al. 2013). However, muscle and liver-specific models of SIRT3 deficiency did not exhibit a metabolic phenotype despite detectable hyperacetylation of mitochondrial proteins; this was potentially explained by compensation by SIRT3 activity in other tissues or key residues unaffected by hyperacetylation (Fernandez-Marcos et al. 2012). PARPs, on the other hand, belong to the ADP-ribosyltransferase family and sequentially transfer ADP-ribose from NAD⁺ to proteins, leading to poly ADP-ribosylation (PARylation) (Decker & Muller 2002, Luo & Kraus 2012). Seventeen different PARPs have been identified in mammals and although they have been recognised to have numerous distinct functions the most well-described function of PARP activity is during DNA repair processes (Decker & Muller 2002). PARP1 is activated by DNA damage and PARylation at these sites leads to recruitment and induction of proteins essential to DNA repair processes (El-Khamisy et al. 2003, Mao et al. 2011, Luo & Kraus 2012). Although not necessarily NAD⁺ dependent, PARP signalling consumes large quantities of cellular NAD⁺ and exhibits a higher affinity for NAD⁺ than SIRTs therefore prolonged PARP activation may deplete cellular NAD⁺ levels (Charron & Bonner-Weir 1999, Ha & Snyder 1999, Kauppinen et al. 2013). Though less well defined, the cADPRs CD38 and CD157 have also been identified as major NAD⁺-consuming enzymes (Aksoy et al. 2006, Graeff et al. 2009). They are transmembrane enzymes and play vital roles in several physiological mechanisms including maintaining calcium (Ca²⁺) homeostasis and immune function (De Flora et al. 1998, Graeff et al. 2009).

**NAD⁺ compartmentalisation**

Distinct subcellular NAD(H) pools were first proposed due to organelle-specific expression of different NAD⁺-generating and -consuming enzymes (VanLinden et al. 2015, Cambronne et al. 2016). Technical advances, most recently in the form and use of fluorescent NAD⁺ biosensors, have provided support for the idea of compartmentalisation of independent NAD⁺ pools within cells. Nucleic and cytosolic NAD⁺ levels are typically found to be interchangeable with NAD⁺ able to pass freely through nuclear membrane pores. Conversely, the mitochondrial membrane is impermeable to NAD⁺ and NADH thus mitochondrial NAD⁺ levels fluctuate independently (Cambronne et al. 2016). A mitochondria-specific pool of NAD⁺ would seem to enable cells to defend oxidative phosphorylation capacity against transient cytoplasmic/nuclear NAD⁺ depletion (Pittelli et al. 2010). NAD⁺ pool size varies in different tissues, for example, cardiac myocytes have an expectedly higher percentage of mitochondrial NAD⁺ compared to cytosolic yet cell type including astrocytes and hepatocytes have a more substantial cytosolic pool (Alano et al. 2007). These differences would seem to reflect the demand on oxidative capacity and function of the different cells. Despite individual NAD⁺ pools, vital crosstalk exists between compartments. Glyceraldehyde-3-phosphate and malate–aspartate shuttles allow the transfer of electrons from cytosolic NADH into the mitochondria and oxidised NAD⁺ is released into the cytosol. Thus, cytosolic NAD⁺ concentrations are an important determinant of mitochondrial NADH flux; meaning major loss of NAD⁺, especially in cells predominantly using carbohydrates as a fuel source, would eventually lead to impaired energy production and ultimately cell death (Easlon et al. 2008).

**Established NAD⁺ biosynthesis pathways**

In mammalian cells, a number of NAD⁺ biosynthesis pathways have been established. These pathways can synthesise NAD⁺ de novo from l-tryptophan or from the salvage of vitamin B3 NAD⁺ precursors nicotinic acid (NA), nicotinamide (NAM) and nicotinamide riboside (NR) (Houtkooper et al. 2010, Dolle et al. 2013) (Fig. 1). The NAD⁺ biosynthesis pathways can be grouped into two distinct routes described as ‘amidated’ or ‘deamidated’ (Mori et al. 2014). De novo synthesis from tryptophan and NA salvage is grouped into the ‘deamidated’ pathway and shares a
final rate-limiting amidation enzyme NADsynthase1 (NADSYN) (Preiss & Handler 1958). Conversely, NAM and NR contain an amide group and therefore follow the ‘amidated’ route to NAD⁺ (Bieganowski & Brenner 2004, Tan et al. 2013, Mori et al. 2014) (Fig. 1). The high turnover of NAD⁺ in most cell types means that a major disruption to these biosynthesis pathways could lead to a severe depletion of cellular NAD⁺ levels and, if sustained, ultimately lead to cell death (Hasmann & Schemainda 2003, Yang et al. 2007).

**De novo biosynthesis**

*De novo* NAD⁺ biosynthesis predominantly begins with the dietary amino acid l-tryptophan. Initially, N-formylkynurenine is generated from tryptophan by the rate-limiting enzyme indoleamine 2,3-dioxygenase or alternatively tryptophan 2,3-dioxygenase. Next, a sequence of four enzymatic reactions convert N-formylkynurenine to α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) (Nikiforov et al. 2011). ACMS can either undergo complete oxidation or spontaneous cyclisation to produce quinolinic acid. The conversion of quinolinic acid to nicotinic acid mononucleotide (NAMN) is catalysed by quinolinate phosphoribosyltransferase (NAMPT) respectively (Preiss & Handler 1958), and NRK1/2 (Mukherjee et al. 2013). These precursors share similar chemical structures and can either be absorbed from the diet or found as a consumed NAD(P)(H) metabolites (Gross et al. 1998, Bieganowski & Brenner 2004, Khan et al. 2006).

NA can be salvaged to NAD⁺ via the Preiss–Handler pathway; initially NA is converted to NAMN in a reaction catalysed by NA phosphoribosyltransferase (NAPRT) with 5-phospho-α-o-ribose-1-diphosphate as its substrate (Preiss & Handler 1958). The pathway then converges with the *de novo* biosynthesis pathway; thus, NAMN is converted to NAAD by NADSYN activity and finally to NAD⁺ by NADSYN (Preiss & Handler 1958). Mammalian NADSYN is a homohexameric protein localised to the cell membrane and is involved in the production of NAD⁺ in various cell types.

Figure 1

Mammalian NAD⁺ biosynthesis pathways. An illustration of mammalian NAD⁺ biosynthesis pathways with exogenous precursor supplementation strategies outlined in green with dashed arrows. NAD⁺ can be generated from Trp *de novo* with multiple enzymatic reactions leading to the production of quinolinic acid (QA), which is then converted to nicotinic acid mononucleotide (NAMN) by QA-phosphoribosyltransferase (QPRTase) and then to nicotinic acid dinucleotide (NaAD) by nicotinamide mononucleotide adenyltransferase (NMMAT) activity, before the final conversion to NAD⁺ by NAD synthase (NADSYN). Alternatively NAD⁺ can be salvaged from precursors and nicotinic acid (QA) by nicotinamide riboside (NaR) by nicotinamide riboside kinases (NRK1/2) respectively to NaMN and finally NDA⁺ by NMMAT. Alternatively, most tissues rely on the amidated routes for NAD⁺ biosynthesis (outlined in red box). Here, nicotinamide riboside (NR) and nicotinamide (NAM) are salvaged by NRKs and nicotinamide phosphoribosyltransferase (NAPRT) respectively to nicotinamide mononucleotide (NMMAT) and ultimately converted to NAD⁺ by NMMAT.
Nicotinamide riboside kinases
Mori + metabolism. 2008. Since then, the
Kitani) that have since been found to
Bieganowski & Brenner 2004). NAMSYN is the final rate-limiting step of
Wang), which is subsequently
Bieganowski and Preiss–Handler pathway and thus makes it a potential antibacterial target, whereas
visfatin, that supposedly exerted insulin mimetic effects
Revollo). Importantly, SIRT activity negatively regulated
expression and activity shown to be modulated by
important of extracellular NAMPT (eNAMPT) remains unclear. It has been proposed that extracellular activity may be part of a wider pathological process whereby
an association between eNAMPT and pro-inflammatory responses including the induction of inducible nitric oxide synthase has been reported (Kieswich et al. 2016).


cytosol. Its enzymatic activity requires co-substrates ATP and glutamine to convert NAAD to NAD\(^+\) and releases AMP, PPi and glutamic acid in the process (Mori et al. 2014). NADS SYN is the final rate-limiting step of both the de novo and Preiss–Handler pathway and thus essential for the generation of NAD\(^+\) via these routes. NADS SYN expression and activity has been shown to be both organism and tissue specific. Some microorganisms including Mycobacterium tuberculosis are dependent on NADS SYN for NAD\(^+\) biosynthesis, which consequently makes it a potential antibacterial target, whereas others use alternative pathways for NAD\(^+\) biosynthesis (Boshoff et al. 2008, De Ingenis et al. 2012). The rate of NADS SYN enzyme activity has been determined in a range of mouse tissues with highest activity levels found in liver and kidney tissue, whereas activity was minimal in brain homogenates and undetectable in lung and skeletal muscle tissues suggesting NAD\(^+\) biosynthesis via the de novo and Preiss–Handler pathways is limited to certain tissues (Mori et al. 2014).

Alternatively, NAD\(^+\) can be salvaged from NAM by the nicotinamide phosphoribosyltransferase (NAMPT) pathway (Tan et al. 2013). In this pathway, NAMPT catalyses the first rate-limiting reaction that converts substrates NAM and 5\(^{\prime}\)-phosphoribosyl-1-pyrophosphate (PRPP) to nicotinamide mononucleotide (NMN) in an ATP-dependent reaction. Then, NMNAT activity allows the conversion of NMN to NAD\(^+\) (Garten et al.). Importantly, NAD\(^+\) consumption by SIRT and PARP activity results in the release of NAM as a reaction product; therefore, salvage by NAMPT provides a central cellular NAD\(^+\) recycling loop. Recycling of NAD\(^+\) via this pathway is tightly regulated in order to sustain appropriate NAD\(^+\) homeostasis, with both NAMPT expression and activity shown to be modulated by cellular NAD\(^+\) levels and SIRT activity negatively regulated by NAM levels (Bitterman et al. 2002).

NAMPT is a dimeric type II phosphoribosyltransferase that is highly conserved and expressed in nearly all the tissues and cells examined suggesting a vital role for NAMPT activity in normal cell function (Wang et al. 2006, Garten et al. 2015). Initially, it was termed pre-B cell colony-enhancing factor (PBEF) due to its proposed cytokine function (Samal et al. 1994); it was then determined to be a hormonal factor, and renamed visfatin, that supposedly exerted insulin mimetic effects (Fukuhara et al. 2005) that have since been found to be unverified (Harasim et al. 2011). NAMPT is both an intracellular and extracellular protein, the intracellular isoform is predominantly localised to the cytosolic and nucleic fractions (Kitani et al. 2003, Revollo et al. 2007).

Within several cell types NAMPT has been shown as a vital enzyme for maintaining cellular NAD\(^+\) and energy homeostasis by recycling NAM to NAD\(^+\) (Yoon et al. 2015, Frederick et al. 2016, Lin et al. 2016, Agerholm et al. 2018, Nielsen et al. 2018). Pharmacological inhibition of NAMPT using the potent inhibitor FK866 results in NAD\(^+\) depletion and for cells that predominantly rely on this pathway for NAD\(^+\) salvage can result in cell death (Hasmann & Schemainda 2003, Tan et al. 2013). The importance of extracellular NAMPT (eNAMPT) remains unclear. It has been proposed that extracellular activity may be part of a wider pathological process whereby ATP and PRPP – both required for NAM salvage and normally found at low levels in the plasma – are released from dying cells into the circulation and drive enzyme activity (Hara et al. 2011, Garten et al. 2015). In diabetes, an association between eNAMPT and pro-inflammatory responses including the induction of inducible nitric oxide synthase has been reported (Kieswich et al. 2016).

**The emergence of the NRK pathway to NAD\(^+\)**

In healthy cells, the vitamin B3 NAD\(^+\) precursors are essential for replenishing NAD\(^+\) for the maintenance of appropriate cellular NAD\(^+\) levels in all compartments supporting energy homeostasis (Bender & Olufunwa 1988, Bogan & Brenner 2008, Dolle et al. 2013). The significance of a requirement for vitamin B3 was first delineated in the disease pellagra, a disorder of B3 deficiency, and since then, increasing evidence has shown that a breakdown in the balance of NAD\(^+\) generation vs NAD\(^+\) consumption is a common factor in numerous morbidities (Pitche 2005).

In 2004, a new pathway to NAD\(^+\) synthesis was determined by Charles Brenner following the identification of nicotinamide riboside kinase 1 (Nrk1) in yeast and subsequent human homologs NRK1 and NRK2 (Bieganski & Brenner 2004, Tempel et al. 2007). In the initial step of the pathway, NRK activity catalyses the phosphorylation of NR to nicotinamide mononucleotide (NMN) (Tempel et al. 2007), which is subsequently converted to NAD\(^+\) by NMNAT (Fig. 2) (Bieganski & Brenner 2004). Alternatively, NRK activity can phosphorylate nicotinic acid riboside (NaR) to nicotinic acid mononucleotide (NaMN), which is then converted to NaAD and finally NAD\(^+\) by NMNAT and NADS YN, respectively (Tempel et al. 2007). The discovery of the NRK enzymes stemmed from previous work that showed NR, as a novel NAD\(^+\) precursor, could extend the lifespan of yeast through the induction of Sir2 in an NAD\(^+\)-dependent manner (Bieganski & Brenner 2004). Since then, the
mounting evidence towards the beneficial effects of using NAD⁺ precursors, and in particular, NR and NMN, has led to the emergence of the NRK enzymes as therapeutic targets. Although the NRK enzymes were identified as an alternative salvage pathway to NAD⁺ (Bieganowski & Brenner 2004), investigations have only recently begun to define the importance of NRK1 and 2 in terms of NAD⁺ metabolism and beyond.

NRK1 and 2 (encoded by Nmrk1 and Nmrk2 genes, respectively) both exhibit a high affinity for NR, yet, their substrate specificity differs (Fig. 1). With ATP as a co-substrate NRK1 has a $K_M$ of 0.088 mM for NR, whereas NRK2 has a $K_M$ of 0.19 mM (Tempel et al. 2007). Furthermore, NRK1 can also use GTP (guanosine triphosphate) as a co-substrate for the phosphorylation of NR yet NRK2 is restricted to ATP (Tempel et al. 2007, Dölle & Ziegler 2009). The enzyme turnover of NR to NMN with ATP has also been estimated; here, the $K_{cat}$ was found to be around 0.6/S for NRK1 and 0.75/S for NRK2 (Tempel et al. 2007). On the other hand, NRK1 and NRK2 exhibit a similar affinity for NaR with a $K_M$ of 0.051 mM and 0.063 mM, respectively (Fig. 1 and Table 1). Further kinetic studies using a pyruvate kinase/lactate dehydrogenase-coupled enzyme assay confirmed these findings with the $K_M$ of NRK1 and 2 found to be in the micromolar range and NRK1 again exhibiting a higher affinity for NR. Interestingly, here they also showed that NRK2 had a 10-fold higher affinity than NRK1 for uridine; yet, they share a similar affinity for cytidine (Dölle & Ziegler 2009).

In mammalian tissues, NRK1 is ubiquitously expressed, whereas NRK2 has been shown to be muscle specific with expression more predominant in skeletal muscle compared to cardiac (Fletcher et al., Ratajczak et al. 2016). Initial studies in zebrafish identified that Nrk2b is a vital component for musculoskeletal development. In Nrk2b-deficient zebrafish muscular abnormalities were identified, including irregular laminin polymerisation at myotendinous junctions and abnormally long muscle fibres that have elongated into adjacent myotomes (Goody et al. 2010). These changes were caused by aberrant cell matrix adhesion complex signalling driven by atypical localisation of Paxillin. It is proposed that the Nrk2b homolog is specifically localised to myotendinous junctions to provide a local NAD⁺ supply, and this may potentially explain why the alternative Nrk homologs are unable to compensate. Importantly, this phenotype was rescued following administration of NAD⁺ demonstrating that the effects were NAD⁺ dependent and that Nrk2b plays a central role in zebrafish NAD⁺ biosynthesis (Goody et al. 2012).

However, murine NRK1 and NRK2 loss-of-function models do not exhibit any gross phenotypic abnormalities, with steady state NAD⁺ levels unaffected, at least in the tissues that have been examined (liver, skeletal muscle, brown adipose and kidney) (Fletcher et al., Ratajczak et al. 2016). Thus, despite the NRK salvage pathway being highly conserved (Bieganowski & Brenner 2004), it appears to play a redundant role in basal murine metabolism; with most tissues examined reliant on the NAMPT salvage pathway to maintain NAD⁺ levels (Fletcher et al., Tan et al. 2015, Frederick et al. 2016, Stromsdorfer et al. 2016, Zhang et al. 2017, Agerholm et al. 2018, Nielsen et al. 2018). The differences seen between zebrafish and murine models following loss of NRK function may be attributed to an absence of alternative NAD⁺ biosynthesis pathways in zebrafish skeletal muscle tissue. Although NRK1 and NRK2 do not appear critical in mice for endogenous NR salvage to NAD⁺, their activity has been determined essential for the utilisation of exogenous NR and, more surprisingly, NMN. Following supplementation, it is

**Table 1** Estimated NRK1 and NRK2 enzyme kinetics and substrate specificity (Tempel et al. 2007).

<table>
<thead>
<tr>
<th>Substrate</th>
<th>$K_M$ (mM)</th>
<th>$K_{cat}$ (S⁻¹)</th>
<th>$K_{cat}/K_M$ (S⁻¹/M)</th>
<th>Substrate specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRK1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NR + ATP</td>
<td>0.088</td>
<td>0.6</td>
<td>6800</td>
<td>ATP, GTP</td>
</tr>
<tr>
<td>NR + GTP</td>
<td>0.068</td>
<td>0.34</td>
<td>5000</td>
<td></td>
</tr>
<tr>
<td>NaR + ATP</td>
<td>0.051</td>
<td>0.21</td>
<td>4100</td>
<td></td>
</tr>
<tr>
<td>NRK2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NR + ATP</td>
<td>0.19</td>
<td>0.75</td>
<td>3900</td>
<td>ATP</td>
</tr>
<tr>
<td>NR + GTP</td>
<td>30</td>
<td>1.7</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>NaR + ATP</td>
<td>0.063</td>
<td>0.34</td>
<td>5400</td>
<td></td>
</tr>
</tbody>
</table>
thought NR is transported into cells via the nicotinamide riboside transporter orthologue of the yeast Nrt1 protein (Belenky et al. 2011).

Without expression of the NRK enzymes in tissues, the NAD\(^+\)-boosting effects of NR and NMN supplementation is blocked, whilst expression of alternative NAD\(^+\) biosynthesis enzymes remains comparable to WT mice (Fletcher et al., Ratajczak et al. 2016). In addition, the NAD\(^+\) boosting effect of NR and NMN supplementation following NAMPT inhibition by FK866 in muscle and hepatic cells is comparable to that of untreated cells. Interestingly, phosphorylation of NR by NRK1 appears preferred to NRK2 even in skeletal muscle where Nmnrk2 is specifically expressed and found at substantially higher mRNA levels than Nmnrk1 (Fletcher et al.). This firstly shows the NRK enzymes exclusively metabolise NR, but it also suggests that NMN must be converted to NR to enter the cell and then be re-phosphorylated intracellularly back to NMN (Fletcher et al., Ratajczak et al. 2016). Previous studies have shown that NMN can be dephosphorylated by cytosolic 5’-nucleotidases and thus it has been postulated that NMN is dephosphorylated to NR extracellularly by the cell membrane protein CD73 (also known as ecto-5-nucleotidase) and then imported into the cell (Kulikova et al. 2015).

Organism and tissue NAD\(^+\) salvage pathway specificity

NAD\(^+\) biosynthesis and salvage enzymes are evolutionarily conserved from bacteria to mammals yet in some organisms certain pathways are preferred (Berger et al. 2004). For example, in mammals, the NAMPT-mediated NAD\(^+\) biosynthesis pathway is essential for maintaining adequate cellular NAD\(^+\) levels and complete absence of the Nampt gene is embryonically lethal (Garten et al. 2015, Tan et al. 2015, Zhang et al. 2017). Despite being well conserved in mammals, the NRK enzymes appear non-essential yet some microorganisms rely on NRK activity to salvage NAD\(^+\) (Fletcher et al., Gazzaniga et al. 2009, Ratajczak et al. 2016). For example, the multifunctional protein NadR is expressed in microorganisms and exhibits both ribosyl/inicotinamide kinase (RNK) activity to phosphorylate NR or NaR, as well as Nmnat activity for NAD\(^+\) biosynthesis. In Haemophilus influenzae, NadR activity is essential for growth yet in microorganisms such as Salmonella enterica serovar Typhimurium, NadR activity is present but not vital (Kurnasov et al. 2002).

The relative importance and tissue specificity of the different precursor molecules in NAD\(^+\) replenishment in vivo is becoming well defined in some tissues but is unclear in others. For example, de novo biosynthesis is thought to be the preferred route for NAD\(^+\) biosynthesis in the liver (Bender et al. 1982, Bender & Olufunwa 1988), with hepatocyte NAD\(^+\) content potentially more resistant to loss of NAMPT function compared to tissues such as muscle and fat (Schuster et al. 2015, Ratajczak et al. 2016). With that said, changes to NAMPT expression in hepatocytes has been shown to alter NAD\(^+\) content and induce physiological changes highlighting that the NAMPT salvage pathway still plays an important role in hepatocyte NAD\(^+\) biosynthesis (Zhou et al. 2016, Mukherjee et al. 2017, Zhang et al. 2017). In the majority of other tissues investigated to date, it is thought that cellular NAD\(^+\) is predominantly attributed to NAD\(^+\) salvage pathways using vitamin B3 precursors found in the diet or as consumed NAD\(^+\) metabolites (Mori et al. 2014). In many of these tissues, direct recycling of NAM is believed to be preferred over NA salvage; with only transient increases in NAD\(^+\) following intraperitoneal injection of NA compared to stable increases following NAM administration (Collins & Chaykin 1972). This is further supported by evidence showing NADSYN activity, the final rate-limiting enzyme in the NA salvage pathway appears inferior to the final rate-limiting step of the amidated pathways (Mori et al. 2014). In mammalian tissue, NR salvage to NAD\(^+\) via the NRK enzymes is not essential and appears limited to NR availability with endogenous NR levels seemingly low in tissues yet exogenous delivery of NR appears highly effective in enhancing NAD\(^+\) directly through NRK activity (Fletcher et al., Ratajczak et al. 2016).

Regulation of the NRK enzymes

Aside from the requirement for NRK1 and/or NRK2 to enhance cellular NAD\(^+\) content following exogenous NR or NMN supplementation, recent data suggest NRK2 may play an an important endogenous role in adaptation to metabolic and energy stress. The regulation of NRK2 has been determined in pathophysiological settings and in response to NAD\(^+\) insufficiency (Fig. 3 – upper panel) (Fletcher et al., Sasaki et al. 2006, Lavery et al. 2008, Aguilar et al. 2015, Xu et al. 2015, Diguet et al. 2017). Following injury to dorsal root ganglion neurons, Nmnrk2 was the most upregulated NAD\(^+\) biosynthetic gene (by over 20-fold), which is surprising considering Nmnrk2 expression is typically absent or detected at low levels in central nervous system tissues (Sasaki et al. 2006). In addition, in a mouse model of traumatic lower limb muscle injury, Nmnrk2 was again found to be significantly
upregulated (three-fold) at 24 h post injury (Aguilar et al. 2015). Mice with a loss of hexose-6-phosphate dehydrogenase (H6PDH) function, an ER-based enzyme required for local NADPH generation, manifest with severe muscle myopathy and on transcriptional analysis Nmrk2 expression was the most dysregulated gene (upregulated by >60-fold mRNA level) (Lavery et al. 2008). Furthermore, Nmrk2 mRNA expression was substantially induced (>80-fold) in models of lethal cardiomyopathy (Xu et al. 2015). In this model, administration with NR was able to increase lifespan of these mice by 50% suggesting that this induction of Nmrk2 in cardiac tissue is to support NAD+ generation (Xu et al. 2015). The hypothesis of Nmrk2 induction to support NAD+ biosynthesis during injury or potentially extreme energetic stress is further supported by its induction during NAD+ depletion. For example, loss of NAD+ by pharmacological inhibition of NAMPT also leads to an induction in Nmrk2 expression, which is normalised when NAD+ levels are restored with NR supplementation (Fletcher et al.).

More recently, in two murine models of the failing heart that cause dilated cardiomyopathy or cardiac hypertrophy, a significant induction of NRK2 – by 40-fold and 4-fold respectively – was determined (Diguet et al. 2017). Conversely, NAMPT expression was downregulated and NAD+ levels were reduced in both models. Similar changes were seen in human failing hearts (Diguet et al. 2017). These findings led to the proposal by Diguet et al. that in NAD+ deficiency, NRK2 may be induced to aid NAD+ biosynthesis. Circulating NR levels are thought to be low or absent (Trammell et al. 2016a) but importantly upon dietary NR supplementation protective effects to
cardiac function were seen (Diguet et al. 2017). They went on to describe the first mechanisms regulating mammalian NRK2 expression. Upregulation of Nmrk2, in response to ATP and NAD+ depletion, suggested Nmrk2 is controlled by energy metabolism signalling pathways (Diguet et al. 2017). Supporting this hypothesis, they found that Nmrk2 was regulated during energetic stress in an AMP-kinase and peroxisome proliferator-activated receptor α (PPARα)-dependent manner in cardiac cells (Diguet et al. 2017).

Intracellular NAD+ concentrations, as well as Sirt1 and Nampt gene expression, have been shown in the liver to be regulated by the circadian clock oscillating in a 24-h rhythm (Nakahata et al. 2009). The expression of these genes and NAD+ levels are impacted by circadian clock gene loss of function and in reverse pharmacological inhibition of NAMPT and loss of NAD+ impacted on circadian gene expression profiles (Nakahata et al. 2009). In addition high-fat diet-fed mouse livers saw remodelling of circadian clock expression and ablation of circadian NAD+, further linking the importance of NAD+ regulation for appropriate circadian clock functioning (Nakahata et al. 2009, Eckel-Mahan et al. 2013). Less is known about the circadian regulation of Nmrk1 and 2. Nmrk1 was recently shown to be circadian regulated in mouse liver tissue and interestingly, like Nampt, Nmrk1 expression was dysregulated in clock-disrupted mice (Mauvoisin et al. 2017).

**NAD+ precursors as therapeutic interventions**

NAD+ has long been associated with disease with symptoms of pellagra first described in the 1800s (Pitche 2005). Pellagra is most commonly caused by malnutrition – more specifically a deficiency in vitamin B3 NAD+ precursors – and is classically characterised by the triad of symptoms; dermatitis, diarrhoea and dementia. Pellagra is historically associated with diets rich in maize, which presents little nutritional value and it was later found that dietary supplementation with NAD+ precursors successfully treated pellagra (Pitche 2005, Naveen et al. 2013).

Since the role of NAD+ as a central metabolic signalling molecule was discovered, there has been a substantial number of studies associating NAD+ availability to metabolic health. A decline in NAD+ in multiple tissues and cell types has been linked to the pathophysiology of ageing and chronic disease states including type II diabetes, neurodegeneration, liver disease and cachexia (Kolttai et al. 2010, Brady et al. 2011, Yoshino et al. 2011, Massudi et al. 2012, Gomes et al. 2013, Long et al. 2015, Camacho-Pereira et al. 2016, Mills et al. 2016, Zhou et al. 2016). Many of these studies implicate reduced SIRT expression and/or activity following a loss of NAD+ and consequently the activity of key SIRT-mediated targets (Kolttai et al. 2010, Brady et al. 2011, Yoshino et al. 2011, Massudi et al. 2012, Gomes et al. 2013, Long et al. 2015, Camacho-Pereira et al. 2016, Zhou et al. 2016). Loss of NAD+ in many of these scenarios may, at least in part, be attributed to elevated PARP activity (Pillai et al. 2005, Brady et al. 2011, Massudi et al. 2012, Lehmann et al. 2016). With increased DNA damage, a hallmark factor of ageing and a consequence of chronic disease, increased PARP activity to induce DNA repair processes can be detrimental to metabolic homeostasis with a decline to cellular NAD+ availability leading to reduced SIRT activity (Decker & Muller 2002, Bai et al. 2011a, Massudi et al. 2012). The importance of NAD+-consuming enzyme crosstalk has previously been established through models of PARP excess and deletion. These models demonstrate a concomitant decrease in NAD+ and SIRT activity following PARP overexpression and an increase in NAD+ content and SIRT-mediated signalling when PARP activity is inhibited (Mangerich et al. 2010, Bai et al. 2011a,b, Luo & Kraus 2012, Mohamed et al. 2014). PARP inhibitors have already shown promise as anticancer agents and now may also be valuable therapeutics against metabolic disease, with PARP inhibition resulting in enhanced oxidative metabolism in mouse models (Bai et al. 2011a,b, To et al. 2014). Recent studies have also implicated CD38 in age-related mitochondrial dysfunction. An increase in CD38 expression was determined in metabolic tissues such as liver, adipose and muscle. Detrimental effects of CD38 in ageing, mediated via a SIRT3 mechanism, were to some extent reversed in CD38 loss-of-function mouse models (Camacho-Pereira et al. 2016).

The knowledge that enhancing NAD+ can induce positive metabolic effects mediated through the induction of SIRT has additionally resulted in a vast array of studies looking at the efficacy of using NAD+ precursors to boost NAD+ (Mouchiroud et al. 2013, Fang et al. 2017, Rajman et al. 2018). NA derivatives have been used clinically for many years, notably in treatment of hypercholesterolemia; however, action on the GPR109A receptor causes undesirable flushing side effects in a large proportion of patients and ultimately leads to poor compliance (Taskinen & Nikkila 1988, Gille et al. 2008, van de Weijer et al. 2015). There has since been major interest in the use of alternative NAD+ precursors that do not activate the GPR109A. Although nicotinamide has been shown to be effective in boosting NAD+ in tissues, concerns regarding the requirement of high doses, which may exert an inhibitory effect on SIRT activity and reduce efficacy
Both NR and NMN have been shown as effective NAD⁺ enhancers in numerous models following supplementation without any notable adverse effects reported to date (Yoshino et al. 2011, Cantó et al. 2012, Khan et al. 2014, Mills et al. 2016, Trammell et al. 2016b, Uddin et al. 2016, Wang et al. 2016, Zhang et al. 2016). The number of studies investigating their therapeutic potential has grown rapidly in recent years. Although these studies have often focussed on one or the other compound, similar and overlapping effects of either NR or NMN supplementation have been reported (Fig. 3 – lower panel). These include NR-mediated NAD⁺ repletion in ageing mice protecting against muscle degeneration, and similarly delayed muscle stem cell senescence in models of muscular dystrophy through improved mitochondrial function resulting in enhanced regenerative capacity and more favourable phenotypes (Zhang et al. 2016). Importantly, the beneficial regenerative effects of NR extended to neural and melanocyte stem cells where it was shown to delay senescence and extend life span (Zhang et al. 2016). NMN supplementation also exhibited positive effects on neurogenesis in aged mice by preserving the neural stem/progenitor cell pool (Stein & Imai 2014). In models of cardiac pathology including ischaemia and reperfusion, heart failure and hypertrophy supplementation with either NMN or NR has resulted in improved outcomes (Yamamoto et al. 2014, Diguet et al. 2017). In metabolic diseases of obesity, diabetes and non-alcoholic fatty liver disease (NAFLD) protective effects of exogenous NR or NMN delivery include enhanced metabolic flexibility, mitochondrial function, improved glucose tolerance, reduced weight gain and prevention of hepatic steatosis and other pathological factors of NAFLD (Yoshino et al. 2011, Cantó et al. 2012, Trammell et al. 2016b, Zhou et al. 2016, Shi et al. 2017) (Fig. 3). There have been many more studies recently published investigating the in vivo effects of NR and NMN supplementation in a variety of disease models, and a more detailed analysis of these has been well described in a number of recent reviews (Fang et al., Rajman et al. 2018).

Currently, the majority of work looking at the benefits of vitamin B3 supplementation has been carried out using animal models; thus, the translational potential to humans is still unclear. Currently, a number of clinical trials focussing on NR and NMN supplementation have recently been completed or are still ongoing. The first clinical study with NR – a double-blind, randomised pharmacokinetic study with 12 participants – found a single oral dose of 1000mg NR raised circulatory NAD⁺ levels by 2.7-fold; interestingly, NAD⁺ metabolomics also identified NAAD as a highly sensitive biomarker for NAD⁺ (Trammell et al. 2016a). In another non-randomised clinical study with eight subjects, a dose-dependent increase in NAD⁺ was found with 250–1000mg/day NR was orally administered over 9 days with a maximal two-fold increase seen in NAD⁺ (Airhart et al. 2017). An 8-week double-blind, randomised clinical trial (n=118) assessing the efficacy and safety of repeat dose NR in combination with the polyphenol molecule pterostilbene, collectively known as NRPT, dosed at either 250mg NR/50mg PT or 500mg NR/100mg PT vs a placebo control group has been conducted (Dellinger et al. 2017). This study provided positive results regarding the safety of repeat dose NRPT and also showed a significant increase in whole blood NAD⁺. In addition, potentially positive effects were observed regarding liver function, which may become more apparent in larger scale clinical trials (Dellinger et al. 2017). In addition, an in-depth analysis of chronic NR supplementation (500mg, twice/day) has recently been investigated in a randomised 6-week, double-blind, placebo-controlled, crossover clinical trial in healthy middle-aged to older adults (n=24). The results from this latest trial further supported previous studies, showing that at this dose, chronic NR was well tolerated by subjects and was also able to enhance NAD⁺ levels of blood cells (Martens et al. 2018). Interestingly, the study also demonstrated some positive trends following NR supplementation in terms of cardiovascular health including NR potentially reducing systolic blood pressure and arterial stiffness (de Picciotto et al. 2016). Again, larger scale clinical trials are now required to establish the potential of NR to exert beneficial effects on these cardiovascular parameters and beyond. There are several ongoing clinical studies that are currently further assessing the safety, efficacy and impact of either NR or NMN supplementation on a wide range of health parameters including vascular endothelial function, immune function, kidney function, muscle mitochondrial function, cognitive function and energy metabolism (see clinicaltrials.gov). Although there is still much to learn regarding the clinical impact of NR and NMN supplementation, currently no adverse effects have been reported (Trammell et al. 2016a, Airhart et al. 2017).

Despite many studies reporting beneficial outcomes in disease models, and the absence of adverse effects from the clinical studies to date, there is still some concern about possible unwanted effects of elevating NAD⁺

with particular focus surrounding immune responses. Numerous mechanistic studies have provided rationale for these concerns with an association found between raised NAD⁺ levels and pro-inflammatory effects (Van Gool et al. 2009, Preyat et al. 2016, Gerner et al. 2017). Notably, secretion of the pro-inflammatory cytokine TNF-α is responsive to intracellular NAD⁺ levels via a proposed SIRT6-based mechanism with loss of SIRT function able to reverse these effects (Van Gool et al. 2009). Although typically thought to be a pro-survival factor, NAD⁺ has also been found to regulate TNF-induced necroptosis, a regulated form of necrosis, via a SIRT-dependent mechanism (Preyat et al. 2016). SIRT1 has also been identified to induce pro-inflammatory effects by promoting T helper 17 effector cell generation and function (Lim et al. 2015). The use of NAMPT inhibitors to deplete cellular NAD⁺ levels has been explored in models of malignancy and inflammation with some studies showing promising effects (Montecucco et al. 2013b). For example, in disease models of colitis where NAMPT is upregulated in response to an increased turnover of NAD⁺ as a result of enhanced activity of NAD⁺-consuming enzymes, NAMPT inhibition was able to markedly suppress key inflammatory processes (Gerner et al. 2017). Similar anti-inflammatory effects have been seen in models of arthritis, experimental autoimmune encephalomyelitis and myocardial ischaemia/reperfusion (Busso et al. 2008, Bruzzone et al. 2009, Montecucco et al. 2013a,b). Although to date there have been no reports of pro-inflammatory effects following vitamin B3 supplementation, these effects may become apparent following long-term precursor supplementation or in certain inflammatory disease states. As many of these pro-inflammatory mechanisms are thought to be mediated by SIRT activity perhaps the rise in nicotinamide, a known inhibitor of SIRT activity, consistently found following NR and NMN supplementation may provide a means of protection against deleterious effects (Bitterman et al. 2002).

**Future research avenues**

Understanding of the importance of NAD⁺ in metabolic health has greatly advanced in recent years and currently research is now focussed on further defining firstly the key pathways vital to maintaining NAD⁺ homeostasis but secondly establishing the most useful pathways to manipulate for enhanced NAD⁺ turnover. Many research challenges still remain including organism, tissue and organelle specificity as well circadian signalling and technical limitations for quantification. The identification of more robust biomarkers to monitor NAD⁺ turnover in health and disease would be extremely valuable.

In terms of clinical importance, many questions are still unanswered regarding the translational likelihood of NR and NMN salvage via the NRK enzymes. These include delivery of appropriate levels of substrate to target tissue, the best route of substrate delivery, dosing and timing taking into account circadian fluctuations in enzymes expression.

Furthermore, the function of NRK2 is still unclear, although it appears to play a redundant role in NAD⁺ biosynthesis along with NRK1, at least in unchallenged models, its highly regulated expression particularly in times of stress suggest it may have role beyond NAD⁺ metabolism.

**Concluding remarks**

The requirement of NRK1 and 2 to utilise exogenous NR and NMN has led to a new found interest into the regulation of this alternative NAD⁺ pathway. The notion of using NAD⁺ precursors to boost NAD⁺ is now beginning to see translation into human studies, appearing to be safe, naturally available, and having the potential to improve health outcomes across a large range of pathophysiological scenarios. NR and NMN supplementation are at the forefront of several clinical trials as a result of mounting evidence from a vast array of in vivo studies supporting their therapeutic potential. Despite this, there is still much more to learn about the NRK enzymes and how best to target NAD⁺ boosting therapies in order for them to maximise their effects. In terms of NAD⁺ biosynthesis, NRK1 appears to play a more crucial role upon exogenous delivery of NR. NRK2 is much more highly regulated with expression typically muscle specific except in times of injury of energetic stress where large changes to expression have been observed. Further work is now necessary to determine whether this induction is a purely adaptive response to acute loss of energy homeostasis or if there is a potential alternative function for NRK2 beyond NAD⁺ metabolism. The induction of NRK activity may also point to the tissues and scenarios in which NR and NMN may be most therapeutically effective.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

**Funding**

GGL is supported by a Wellcome Trust Senior Fellowship (grant number-104612/Z/14/Z).

Agullar CA, Shcherbina A, Rike DO, Pop R, Carrigan CT, Gifford CA, Urso ML, Kottke MA & Meissner A 2015 In vivo monitoring of transcriptional dynamics after lower-limb muscle injury enables quantitative quantification of healing. Scientific Reports 5 13885. (https://doi.org/10.1038/srep13885)


De Flora A, Franco L, Guida L, Bruzzone S & Zocchi E 1998 Ectocellular CD38-catalyzed synthesis and intracellular Ca(2+)-mobilizing activity


Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L & Marchelli E 2017 Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. *NPJ Aging and Mechanisms of Disease* **3** 17. (https://doi.org/10.1038/s41514-017-0016-9)


Hara N, Yamada K, Shibata T, Osago H & Tsuchiya M 2011 Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLOS ONE 6 e22781. (https://doi.org/10.1371/journal.pone.0022781)


Harden A & Young WI 1906 The alcoholic ferment of yeast juice. Proceedings of the Royal Society B: Biological Sciences 78 369–375. (https://doi.org/10.1098/rspb.1906.0070)


Walsh CT, Tu BP & Tang Y 2018 Eight kinetically stable but thermodynamically activated molecules that power cell metabolism. Chemical Reviews 118 1460–1494. (https://doi.org/10.1021/acs.chemrev.7b00510)


Zhao G 2015 Inhibition of nicotinamide phosphoribosyltransferase. Cell Death and Disease 6 1185–1201. (https://doi.org/10.1038/cddis.2015.186)